Phase I Keynote 001 trial, showed that patients with treatment-naive NSCLC and PD-L1 TPS of not more than 50% benefited from pembrolizumab, achieving a 58.3% RR, 12.5 months of median PFS, and a 24-month OS rate of 60.6% [147]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.